FDA clears Elekta's device for cranial cancer therapy

02/21/2012 | PharmaBiz.com (India)

The FDA has granted Elekta 510(k) clearance for Fraxion, which is billed as the first advanced technology to integrate into a single system all proven options for cranial immobilization. The Fraxion head frame is designed to allow clinicians to more accurately deliver stereotactic radiation therapy of cranium and brain cancer targets.

View Full Article in:

PharmaBiz.com (India)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA